The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books
Jun 10, 2020 • 42min
Ep71: Andy Plump
Takeda R&D president Andy Plump on fighting COVID19 and racism.
May 26, 2020 • 1h 5min
Ep70: Nina Kjellson
Nina Kjellson forging a path in biotech venture capital.
May 14, 2020 • 35min
Vaccine Strategy with Larry Corey
Ep69 of The Long Run with virologist Larry Corey
Apr 30, 2020 • 41min
Ep68: Emma Hodcroft
Emma Hodcroft on NextStrain and viral evolution
Apr 17, 2020 • 36min
Ep67: George Scangos
George Scangos of VIR on neutralizing antibodies for SARS-CoV-2
Apr 5, 2020 • 38min
Ep66: Mike Pellini
In this conversation, Mike Pellini, managing partner at Section 32 and former CEO of Foundation Medicine, dives deep into the world of diagnostic testing, particularly during the COVID-19 pandemic. He critiques the federal testing failures and discusses the need for a cohesive national framework. Pellini emphasizes the critical yet overlooked role of diagnostic testing in healthcare decision-making and advocates for better recognition and funding. He also highlights logistical challenges and the importance of data aggregation in enhancing public health management.
Mar 24, 2020 • 58min
Ep65: Alexis Borisy & Melanie Nallicheri
Leaders of EQRx, a company aspiring to make novel drugs at low prices.
Mar 9, 2020 • 49min
Ep64: Isabella de la Houssaye
Isabella is a Stage 4 lung cancer patient on a mission.
Feb 25, 2020 • 59min
Ep63: Jeremy Levin
Jeremy Levin, chairman of BIO, on the perilous moment in politics.
Feb 11, 2020 • 56min
Ep62: Jane Grogan
Jane Grogan, CSO of Arsenal Bio, on programmable cell therapies.
